Key facts
- This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 02 Aug 2024, 17:28.
Patrick Lin - 05 Apr 2024 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)
- Reporting relationship
- Chief Business - Strategy Off
- Issuer ticker
- PCSA
- Reported as of
- 05 Apr 2024
- Net transaction value
- -$1,967
- SEC form
- 4
- Accepted by SEC
- 02 Aug 2024, 17:28:43 UTC
- Prior SEC filing
- 01 Feb 2024
- Next SEC filing
- 29 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 02 Aug 2024.
Change
- Previous filing in this sequence was filed on 01 Feb 2024.
- Current net transaction value: -$1,967.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCSA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,675
- Change %
- +6.1%
- Price
- Shares after
- 29,225
- Date
- 05 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
PCSA
transaction
Common Stock
Tax liability
- Transaction value
- $1,504
- Shares
- -539
- Change %
- -1.8%
- Price
- $2.79
- Shares after
- 28,686
- Date
- 05 Apr 2024
- Ownership
- Direct
PCSA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +644
- Change %
- +2.2%
- Price
- Shares after
- 29,330
- Date
- 10 Jul 2024
- Ownership
- Direct
- Footnotes
- F1
PCSA
transaction
Common Stock
Tax liability
- Transaction value
- $463
- Shares
- -271
- Change %
- -0.92%
- Price
- $1.71
- Shares after
- 29,059
- Date
- 10 Jul 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PCSA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +2,713
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 22,201
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,713
- Exercise price
- $0.000000
- Footnotes
- F2
PCSA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +2,035
- Change %
- +9.2%
- Price
- $0.000000
- Shares after
- 24,236
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,035
- Exercise price
- $0.000000
- Footnotes
- F3
PCSA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +339
- Change %
- +1.4%
- Price
- $0.000000
- Shares after
- 24,575
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 339
- Exercise price
- $0.000000
- Footnotes
- F4
PCSA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +339
- Change %
- +1.4%
- Price
- $0.000000
- Shares after
- 24,914
- Date
- 28 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 339
- Exercise price
- $0.000000
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Distribution of vested restricted shares.
Footnote F2
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
Footnote F3
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
Footnote F4
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.